The present disclosure is directed to formulations, devices, kits, and methods for treating or preventing motor symptoms associated with Parkinson's disease by injection of a microsphere formulation of apomorphine free base or a pharmaceutically acceptable a salt thereof, wherein injection can be from a pre-filled injector.

Procedure for the purification of biodegradable thermoplastic polymer particles for medical and/or pharmaceutical use without the use of organic solvents, as well as the particles obtained themselves, and the use of polymeric particles obtained by this procedure to manufacture parenteral administered medicinal products and/or implantable medical devices.

The invention provides a slow-release material comprising particles, wherein the particles comprise a core comprising an active component and a multilayer shell, wherein the multi-layer shell comprises a molecular layer deposition (MLD) multi-layer, wherein the active component comprises one or more of a pharmaceutical compound and a nutraceutical compound, for use in the treatment of a disease.

The present invention relates to a process for the production of a microcapsule comprising an active ingredient or inactive precursor thereof, as well as a microcapsule obtainable thereby. The process involves the use of a surface-reacted calcium carbonate as a template for encapsulating the active ingredient or inactive precursor thereof. The active ingredient or inactive precursor thereof is loaded onto the surface-reacted calcium carbonate and subsequently encased by a multilayer shell comprising at least two complementary layers using layer-by-layer assembly. Further aspects of the invention relate to the use of a surface-reacted calcium carbonate as a template for encapsulating the active ingredient or inactive precursor thereof, a product comprising said microcapsule, as well as the use of said microcapsule.

The present disclosure provides methods of reducing the level of acetylated Tau in a neuron or a glial cell in an individual, the methods involving administering to the individual a prodrug that is converted in the individual to salicylate. The present disclosure provides methods of treating a tauopathy in an individual, the methods involving administering to the individual a prodrug that is converted in the individual to salicylate.

The present invention relates to an application of a traditional Chinese medicine composition and formulation thereof in the preparation of medicaments for preventing and/or treating novel coronavirus pneumonia.

Particles, compositions, and methods that aid particle transport in mucus are provided. The particles, compositions, and methods may be used, in some instances, for ophthalmic and/or other applications. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles, such as particles of pharmaceutical agents that have a low aqueous solubility. Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye.

Implantable devices including a biocompatible matrix configured for long term location in adipose tissue and a biologically active agent that can be carried by the matrix and delivered to the adipose tissue following implant therein. The biologically active agent can include a modulator or a precursor thereof that can directly or indirectly modify the gene expression of adipose cells, e.g., adipocytes, and thereby modify the presence or quantity of one or more expression products of the adipose tissue that may act locally on distant from the implant site in an endocrine fashion. Modulators can include small molecules (e.g., resveratrol), polynucleotides (e.g., RNAi), or polypeptides (e.g., antibodies or functional fragments thereof).

A method for treating an ocular disorder in a subject comprising administering a therapeutic agent-loaded carrier to an ocular site of the subject in need thereof, wherein the therapeutic agent loaded-carrier provides controlled delivery of the therapeutic agent under conditions suitable for recruiting regulatory T cells to an ocular region of interest or inducing regulatory T cells in an ocular region of interest.

Dendrimer-based compositions and methods are provided, that are useful for administering pharmaceutical compositions to target cells and tissues for treatment of ocular diseases including macular degeneration, diabetic retinopathy, and retinitis pigmentosa.